C.Q. Pharmaceutical Holding (000950) Fundamentals 2026 — P/E 21.2x, Revenue Analysis | SniperIQ
C.Q. Pharmaceutical Holding (000950) is a CN-listed Healthcare company in Medical - Care Facilities with a market capitalization of ¥9.1B, trading at ¥5.32 on the SHZ. This SniperIQ fundamentals page covers C.Q. Pharmaceutical Holding's valuation (P/E 21.2x, P/B 0.8x), profitability (net margin 0.5%), revenue (¥82.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is C.Q. Pharmaceutical Holding's market cap?
C.Q. Pharmaceutical Holding (000950) has a market capitalization of approximately ¥9.1B, trading at ¥5.32 on the SHZ. Market cap moves with the live share price.
What is C.Q. Pharmaceutical Holding's P/E ratio?
C.Q. Pharmaceutical Holding's trailing twelve-month P/E ratio is 21.2x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is C.Q. Pharmaceutical Holding?
C.Q. Pharmaceutical Holding runs a net profit margin of 0.5%, a gross margin of 7.1%, and an operating margin of 0.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does C.Q. Pharmaceutical Holding generate?
C.Q. Pharmaceutical Holding reported revenue of ¥82.4B for fiscal year 2025, with net income of ¥387M and earnings per share (EPS) of 0.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does C.Q. Pharmaceutical Holding pay a dividend?
C.Q. Pharmaceutical Holding offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is C.Q. Pharmaceutical Holding financially healthy?
C.Q. Pharmaceutical Holding carries a debt-to-equity ratio of 2.50x and a current ratio of 1.20x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is C.Q. Pharmaceutical Holding a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For C.Q. Pharmaceutical Holding (000950) the key facts are: market cap ¥9.1B, P/E 21.2x, revenue ¥82.4B, 52-week range 4.79-7.41. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track C.Q. Pharmaceutical Holding's full fundamentals live
Get C.Q. Pharmaceutical Holding's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.